August 8, 2024 11:49 AM EDT
R&D

Lil­ly’s an­ti-tau pill for Alzheimer’s fails in Phase 2 study

Ryan Cross

Senior Science Correspondent

One month af­ter the long-await­ed ap­proval of its first Alzheimer’s drug, Eli Lil­ly said that an­oth­er ex­per­i­men­tal med­i­cine aimed at slow­ing de­men­tia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times